Article in Journal of immunology (Baltimore, Md. : 1950), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
6 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors at 2 institutions in 1 country.
Run XiaoDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH.
Anthony G MansourDepartment of Hematological Malignancies and Stem Cell Transplantation, City of Hope National Medical Center and the Beckman Research Institute, Los Angeles, CA.ORCID 0000-0002-6986-6203
Wei HuangDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH.ORCID 0000-0002-1775-6512
Quais N HassanDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH.
Ryan K WilkinsDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH.
Suraj V KomatineniDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH.
Rhiannon BatesDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH.
Seemaab AliDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH.ORCID 0000-0002-5337-8782
Logan A ChrislipDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH.ORCID 0000-0002-8842-147X
Nicholas J QueenDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH.ORCID 0000-0003-1864-5790
Shoubao MaDepartment of Hematological Malignancies and Stem Cell Transplantation, City of Hope National Medical Center and the Beckman Research Institute, Los Angeles, CA.ORCID 0000-0002-8397-7604
Jianhua YuDepartment of Hematological Malignancies and Stem Cell Transplantation, City of Hope National Medical Center and the Beckman Research Institute, Los Angeles, CA.ORCID 0000-0002-0326-3223
Matthew R LordoThe Ohio State University Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, Columbus, OH.ORCID 0000-0002-7108-9765
Bethany L Mundy-BosseThe Ohio State University Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, Columbus, OH.
Michael A CaligiuriDepartment of Hematological Malignancies and Stem Cell Transplantation, City of Hope National Medical Center and the Beckman Research Institute, Los Angeles, CA; lei.cao@osumc.edu mcaligiuri@coh.org.ORCID 0000-0002-4095-3020
Lei CaoDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH; lei.cao@osumc.edu mcaligiuri@coh.org.ORCID 0000-0003-0322-4985
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USCity Of Hope National Medical Center · US
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
The Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI Balveen Kaur · 2013 to 2026
$26.0M
Human natural killer cells: Advancing biology and clinical applicationsR35CA210087 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2017 to 2026
$8.3M
IL-15--CHARACTERIZATION THROUGH EXPERIMENTAL IMMUNOLOGYR01CA068458 · NCI · ROSWELL PARK CANCER INSTITUTE · PI CALIGIURI, MICHAEL A, YU, JIANHUA · 1996 to 2019
$4.5M
Cancer Prevention and Treatment by Activation of a Brain-Adipocyte AxisR01CA166590 · NCI · OHIO STATE UNIVERSITY · PI CAO, LEI · 2013 to 2022
$3.4M
Overcoming Barriers of Virotherapy by Next-Generation oHSV Expressing E-CadherinR01NS106170 · NINDS · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2018 to 2023
$1.9M
Enhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer PreventionR01CA185301 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A, YU, JIANHUA · 2015 to 2019
$1.8M
The role of hypothalamic-sympathoneural-adipocyte axis in healthy agingR01AG041250 · NIA · OHIO STATE UNIVERSITY · PI CAO, LEI · 2013 to 2017
$1.6M
IL-15 characterization through experimental immunologyR37CA068458 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A · 2010 to 2014
$1.4M
Identifying brain mediators distinguishing eustress and distress impact on cancerR01CA163640 · NCI · OHIO STATE UNIVERSITY · PI CAO, LEI · 2013 to 2017
$1.2M
The role of hypothalamic-sympathoneural-adipocyte axis in healthy agingR56AG041250 · NIA · OHIO STATE UNIVERSITY · PI CAO, LEI · 2019 to 2019
$390k
Group 1 Innate Lymphoid Cell Dysregulation in Acute Myeloid LeukemiaF30CA250244 · NCI · OHIO STATE UNIVERSITY · PI LORDO, MATTHEW · 2022 to 2025
CD1d, a lipid Ag-presenting molecule for invariant NKT (iNKT) cells, is abundantly expressed on adipocytes and regulates adipose homeostasis through iNKT cells. CD1d gene expression was restored in visceral adipose tissue adipocytes of CD1d knockout (KO) mice to investigate the interactions between adipocytes and immune cells within adipose tissue. We developed an adipocyte-specific targeting recombinant adeno-associated viral vector, with minimal off-target transgene expression in the liver, to rescue CD1d gene expression in visceral adipose tissue adipocytes of CD1d KO mice, followed by assessment of immune cell alternations in adipose tissue and elucidation of the underlying mechanisms of alteration. We report that adeno-associated virus-mediated gene transfer of CD1d to adipocytes in CD1d KO mice fails to rescue iNKT cells but leads to massive and selective expansion of T cells within adipose tissue, particularly CD8
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Adipocyte CD1d Gene Transfer Induces T Cell Expansion and Adipocyte Inflammation in CD1d Knockout Mice. · full record | OpenQuestion